Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility ... million), and could create 300 jobs at the plant itself, with another 500 positions required ...

Eli Lilly will spend $3 billion expanding ... add 750 workers to the current tally of 100 at the plant. The expanded facility will focus on manufacturing "injectable medicines, device assembly ...

MILWAUKEE — Microsoft bought 240 acres of land from Kenosha with goals for future data center development.

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

Online master’s degrees in engineering and education from Purdue again rank among the nation’s finest. Four of Pur ...

Neurocrine Biosciences, Inc. today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device. In this role, Dr. Ratz will lead the ...

Microsoft boguht 240 acres in Kenosha, Wis. for future data center development, a boost for local innovation and economic ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...